EDWARDS LIFESCIENCES has been Sued for Securities Fraud after Stock Plummets 31%; Contact the Firm before December 13 Class Action Deadline (NYSE:EW)

Lawsuit Overview - A lawsuit has been filed against Edwards Lifesciences Corporation and certain senior executives for potential violations of federal securities laws [1] - The lawsuit is pending in the U S District Court for the Central District of California under the case Patel v Edwards Lifesciences Corporation et al No 24-cv-02221 [2] - Investors have until December 13 2024 to ask the Court to be appointed as lead plaintiff [2] Allegations Against Edwards Lifesciences - Edwards Lifesciences is accused of making materially false and misleading statements regarding its TAVR platform and its ability to capitalize on unmet demand [4] - The company allegedly overstated the demand and growth potential of TAVR while its patient activation activities failed to reach the low-treatment-rate population [4] - Healthcare organizations prioritized other treatments over TAVR leading to underutilization despite the company's claims of a significantly undertreated patient population [5] Financial Impact - On July 24 2024 Edwards Lifesciences slashed its guidance for TAVR for fiscal 2024 and announced disappointing financial results for TAVR in fiscal 2Q 24 [5] - The news caused a 31% decline in Edwards stock price from $86 95 per share on July 24 2024 to$59 70 per share on July 25 2024 [6] Company Background - Edwards Lifesciences is an international company that researches develops and provides products and technologies for heart valve repair and replacement therapies as well as critical care monitoring solutions [3] - The company categorizes its therapies and technologies into four segments: Transcatheter Aortic Valve Replacement (TAVR) Transcatheter Mitral and Tricuspid Therapies (TMTT) Surgical Structural Heart therapies and Critical Care therapies [3] Legal Representation - Bleichmar Fonti & Auld LLP is representing plaintiffs in this securities class action and shareholder litigation [8] - The firm has a track record of recovering significant amounts in similar cases including $900 million from Tesla Inc's Board of Directors and$420 million from Teva Pharmaceutical Ind Ltd [8]